Ribavirin attenuates carcinogenesis by downregulating IL-6 and IL-8 in vitro in human lung adenocarcinoma

• Published in: Pathology, research and practice research and practice, 2024-01, Vol.253, p.155038-155038, Article 155038
• Main Authors: De Rubis, Gabriele, Paudel, Keshav Raj, Yeung, Stewart, Agarwal, Vipul, Hansbro, Philip Michael, Oliver, Brian Gregory George, Dua, Kamal
• Format: Article
• Language: English
• Subjects: Drug repurposing; IL-6; IL-8; Interleukins; Lung cancer; Ribavirin
• ISSN: 0344-0338; 1618-0631
• DOI: 10.1016/j.prp.2023.155038

Lung cancer is one of the leading causes of death worldwide, whereby the major contributing factors are cigarette smoking and exposure to environmental pollutants. Despite the availability of numerous treatment options, including chemotherapy, the five-year survival rate is still extremely low, highlighting the urgent need to develop novel, more effective therapeutic strategies. In this context, the repurposing of previously approved drugs is an advantage in terms of time and resources invested. Ribavirin is an antiviral drug approved for the treatment of hepatitis C, which shows potential for repurposing as an anticancer agent. Among the many signaling molecules promoting carcinogenesis, the interleukins (ILs) IL-6 and IL-8 are interesting therapeutic targets as they promote a variety of cancer hallmarks such as cell proliferation, migration, metastasis, and angiogenesis. In the present study, we show that ribavirin significantly downregulates the expression of IL-6 and IL-8 in vitro in A549 human lung adenocarcinoma cells. The results of this study shed light on the anticancer mechanisms of ribavirin, providing further proof of its potential as a repurposed drug for the treatment of lung cancer. [Display omitted]